Pricing Log in Create free account

MiMedx Group, Inc (MDXG) vs Monopar Therapeutics Inc. (MNPR)

MiMedx Group, Inc and Monopar Therapeutics Inc. are both Biotechnology companies. MiMedx Group, Inc and Monopar Therapeutics Inc. are of similar size ($478.6M and $451.2M). Monopar Therapeutics Inc. has the higher net margin (0.00% vs −6.32%) and the higher return on invested capital (0.00% vs −17.4%). Across the 12 metrics below, MiMedx Group, Inc leads on 6 and Monopar Therapeutics Inc. on 6.

Valuation

Metric MDXG MNPR Biotechnology median
P/E n/m n/m 10.60
P/S 1.59 n/m 9.40
P/B 2.29 4.66 2.13
Price to free cash flow 25.38 n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1.25 n/m 9.02
Earnings yield (3.91%) (3.04%) (32.88%)
Free cash flow yield 3.94% (2.00%) (23.13%)

Profitability

Metric MDXG MNPR Biotechnology median
Gross margin 77.29% — 68.51%
Operating margin (8.28%) 0.00% 0.00%
Net margin (6.32%) 0.00% 0.00%
Free cash flow margin 6.26% 0.00% 0.00%
Return on equity (8.53%) (19.50%) (51.96%)
Return on assets (6.58%) (18.90%) (46.06%)
Return on invested capital (17.40%) 0.00% 0.00%

Growth

Metric MDXG MNPR Biotechnology median
Revenue growth (TTM) (22.80%) — 6.76%
EPS growth (last fiscal year) 14.29% 54.99% 29.88%
Revenue growth, 5-year CAGR 11.02% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MDXG MNPR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.35 33.56 4.97
Net debt to EBITDA (1.88) 8.06 1.01

Dividend

Metric MDXG MNPR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MDXG MNPR Biotechnology median
Market cap 478.63m 451.19m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack